Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Animal models of Multiple Sclerosis

Claudio Procaccini a, Veronica De Rosa a,b, Valentina Pucino c, Luigi Formisano d, Giuseppe Matarese e,f,*

a Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEDS-CNIR) © Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli "Federico II", 80131 Napoli, Italy
b Unità di Neuroimmunologia, IRCCS Fondazione Santa Lucia, 00143 Roma, Italy
c Dipartimento di Scienze Mediche, Università degli Studi di Salerno, Baronissi Campus, 84081 Baronissi, Salerno, Italy
d Divisione di Farmacologia, Dipartimento di Scienze e Tecnologie, Università degli Studi del Sannio, 82100 Benevento, Italy
e IRCCS Multimedica, 20138 Milano, Italy
f Dipartimento di Medicina e Chirurgia, Università degli Studi di Salerno, Baronissi Campus, 84081 Baronissi, Salerno, Italy

Abstract

Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) which involves a complex interaction between immune system and neural cells. Animal modeling has been critical for addressing MS pathogenesis. The three most characterized animal models of MS are (1) the experimental autoimmune/allergic encephalomyelitis (EAE); (2) the virally-induced chronic demyelinating disease, known as Theiler’s murine encephalomyelitis virus (TMEV) infection and (3) the toxin-induced demyelination. All these models, in a complementary way, have allowed to reach a good knowledge of the pathogenesis of MS. Specifically, EAE is the model which better reflects the autoimmune pathogenesis of MS and is extremely useful to study potential experimental treatments. Furthermore, both TMEV and toxin-induced demyelination models are suitable for characterizing the role of the axonal injury/repair and the remyelination process in MS. In conclusion, animal models, despite their limitations, remain the most useful instrument for implementing the study of MS.

1. Introduction

Multiple Sclerosis (MS) is a chronic immune-mediated demyelinating disease of the central nervous system (CNS) (Hafler et al., 2005). It represents the leading cause of non-traumatic disability among young adults and has a great socio-economic impact in developed countries. MS is a very heterogeneous disease, indeed its clinical signs and symptoms are very variable and depend on the parts of the affected CNS (brain and spinal cord), including motor, sensory, autonomic and cognitive disabilities (Noseworthy et al., 2000). It can run at least three clinical courses: the relapsing–remitting (RR), which is the most frequent (85%) and it is characterized by exacerbations and subsequent periods of clinical stability; secondary progressive (SP) and the primary-progressive (PP) subtype (Noseworthy et al., 2000). CNS tissue from Multiple Sclerosis patients shows discrete lesions with inflammatory infiltrates, demyelination, astrogliosis and early axonal damage. MS is widely considered an autoimmune demyelinating disease, where an autoimmune reaction by myelin-specific CD4+ T helper 1 (Th1) and Th17 cells, which initiate the neuropathology, has been described (Hafler et al., 2005; Sospedra and Martin, 2005). A specific cause for the pathogenesis of MS has not been identified so far, although several genetic and environmental risk factors have been suggested to play a central role. In this context, animal models of MS had allowed to explore mechanisms of disease initiation and progression and test several novel therapeutic approaches for the disease.

2. Positive and negative aspects of MS animal models

Since MS is a complex disease, there is no a single animal model that can capture the entire spectrum of heterogeneity of human MS and its variety in clinical and radiological presentation. However, over the last few years, animal models have been used to study the pathogenic mechanisms of MS. The main positive aspect is that they can surely serve as a testing tool to study disease development and for novel therapeutic approaches. In addition, they are a relatively convenient source of tissue from the CNS, which is the main target of MS, in contrast to human tissues, biopsies, or autopsy samples which are rarely performed. Several researchers have recently raised...
the question whether these animal models could really represent a good model for MS since they do not perfectly reflect all the aspects of the human disease. In particular, disease initiation is usually highly artificial in the animal models (induced by active immunization with an auto-antigen). Also the time-frame of the clinical symptoms onset is different between humans and mice. In humans, physiological processes underlying the disease are undetected for years before the onset of clinical manifestations, while symptoms in the animal models can be detected within weeks or even days after induction of the disease. Moreover the treatment in these therapy studies started very early in the course of the induced autoimmune disease, whereas any therapy for humans is administered in a late phase of the disease. More importantly, most of the experimental studies use inbred strains mice with genetic homogeneity and often these mice may have accumulated genetic irregularities that are very difficult to find in human population. Although it has become clear that rodent and human immune systems have profound differences (as they are evolutionarily distant), they share some essential principles and, in this context, the availability of three major animal models of MS allowed the understanding of relevant features of the human MS. The most commonly studied animal models of MS are (1) the experimental autoimmune/allergic encephalomyelitis (EAE); (2) viral induced models, mainly Theiler's murine encephalomyelitis virus (TMEV) infection and consequential chronic demyelination and (3) toxin-induced models of demyelination, such as the cuprizone and the lyso-phosphatidylcholine (lysolecithin) models.

3. Experimental autoimmune encephalomyelitis (EAE)

MS is a chronic, immune-mediated, inflammatory disorder of the CNS (Frohman et al., 2006). The most-studied animal model of MS is the experimental autoimmune encephalomyelitis (EAE), in which autoimmunity to CNS components is induced in susceptible mice through immunization with self-antigens derived from basic myelin protein. Rivers et al. (1933) firstly described, in monkeys immunized with rabbit brain extracts, paralysis associated with perivascular infiltrates and demyelination in the brain and spinal cord, as acute disseminated encephalomyelitis, later called experimental autoimmune encephalomyelitis (EAE). Freund’s adjuvant (CFA) (Freund and McDermott, 1942) and pertussis toxin (PT) (Munoz et al., 1984), were later added to potentiate the humoral immune response and to induce oscillatory symptoms typical of the relapsing–remitting disease (Kabat et al., 1947), similar to that found in MS patients. Experiments were also performed in other animal species such as guinea pigs (Freund et al., 1947), monkeys (Kabat et al., 1947; Morgan, 1947); however mice (Olitzky and Yager, 1949) and rats (Lipton and Freund, 1952) resulted the best model to evaluate acute monophasic, relapsing–remitting and chronic progressive EAE through immunogenetic, histopathological and therapeutic studies. EAE in mice is characterized by an ascending paralysis beginning at the tail (Batoulis et al., 2011), followed by limb and forelimb paralysis, assessed by using a 5-points scale (McRae et al., 1992; Rangachari et al., 2012; Berard et al., 2010). EAE may be induced in mice with different genetic backgrounds, such as SJL/J, C57BL/6 and NOD, through either active immunization with protein or peptide, or by passive transfer of encephalitogenic T cells. In all cases, the relevant immunogen is derived from self-CNS proteins such as myelin basic protein (MBP), proteolipid protein (PLP) or myelin oligodendrocyte glycoprotein (MOG). Immunization of SJL/J mice with the immunodominant epitope of PLP (PLP139-151) induces a relapsing–remitting (RR) disease course (Tuohy et al., 1989), while disease induced by the immunodominant MOG35-55 peptide in C57BL6/J mice is of chronic nature (Tomkins et al., 2002).

More recently a variety of additional antigens have been supposed to be involved in autoimmune reaction in MS and EAE. Some of them are myelin constituents, such as neurofascin NF 155 (Mathey et al., 2007), others are expressed on myelin and axons, such as contactin-2/transient axonal glycoprotein-1 (TAG-1) (Derfuss et al., 2009) and some other are entirely non-myelin antigens, such as the neuronal membrane protein neurofascin NF 186 (Mathey et al., 2007), the neuronal cytoskeletal protein

### Table 1

Characteristics of the different mouse models of multiple sclerosis.

| Model of MS          | Mechanism                              | Application                                      | Involved cells                                      | Translational value                              | Main references                           |
|----------------------|----------------------------------------|--------------------------------------------------|-----------------------------------------------------|--------------------------------------------------|-------------------------------------------|
| Relapsing–remitting EAE in SJL/J mice | Immunization of SJL/J mice with PLP139-151 | Study of neuroinflammation and immune system activation | CD8, CD4, Th17, monocytes, macrophages, B cells, Treg cells | Relapsing–remitting MS, study of the relapse rate, testing therapeutical agents | Zaoui et al., 1985; McRae et al., 1995; Whitham et al., 1991; Miyagawa et al., 2010; Aidiard et al., 1999 | Mendel et al., 1995; Berard et al., 2010; Hjelmstrom et al., 1998; Bullard et al., 2007; Koh et al., 1992; Baron et al., 1993; Bettelli et al., 2003; Litzenburger et al., 1998; Jager et al., 2009; Encinas et al., 1999; Anderson et al., 2012 |
| Chronic EAE in C57BL/6J mice | Immunization of C57BL/6J mice with MOG35-55 | Study of neuroinflammation and immune system activation | CD8, CD4, Th17, monocytes, macrophages, B cells, Treg cells | Primary progressive MS, secondary progressive MS, testing therapeutical agents | EAE in transgenic mice | Tsuboi et al., 1996; Tsunoda et al., 1996; Tsunoda and Fujinami, 2010; Libby and Fujinami, 2003; Owens, 2006; Tsunoda et al., 1996; Tsunoda et al., 2003 |
| EAE in transgenic mice | T cell clone (2D2) expressing Vα and Vβ chains reacting specifically to MOG35-55, or B cell heavy chain knock-out mouse strain (tg8 MOG) | Study of neuroinflammation and immune system activation | CD8, CD4, Th17, monocytes, macrophages, B cells, Treg cells | In vitro study of immune cell activation and function | Theiler's murine encephalomyelitis virus (TMEV) | Jager et al., 1997; Litzenburger et al., 1998; Jager et al., 2009; Encinas et al., 1999; Anderson et al., 2012 |
| Cuprizone-induced MS | Feeding C57BL/6 mice with 0.2% cuprizone for 6 weeks | Study of the demyelination processes | Oligodendrocytes, astrocytes, microglia | Therapeutical trials designed to repress demyelination or accelerate remyelination | Therapeutical trials designed to repress demyelination or accelerate remyelination |                |
| Lysolecithin-induced MS | Lysolecithin injection in SJL/J mice | Study of the demyelination processes | Oligodendrocytes, astrocytes, microglia | Therapeutical trials designed to repress demyelination or accelerate remyelination | Therapeutical trials designed to repress demyelination or accelerate remyelination |                |
neurofilament-M (Krishnamoorthy et al., 2009) and the astrocyte-typical Ca2+-binding protein S100b.

3.3. Transgenic mice

Bettelli et al. (2003) firstly generated a class II-restricted TCR transgenic model to study MOG35–55-induced EAE by using a C57BL/6J background (Table 1). An epitope-reactive T cell clone (2D2) was obtained which expressed V\(\alpha\) and V\(\beta\) chains reacting specifically to MOG35–55. These 2D2 mice also showed a more severe EAE than non-transgenic littermate with a high frequency to develop spontaneous EAE. Another transgenic mouse model used to study EAE was a B cell heavy chain knock-in mouse strain (IgH MOG; also known as TH), that contains a high frequency of anti-MOG antibody-secreting B cells in the peripheral repertoire. Upon active immunization with recombinant MOG, IgH MOG animals develop EAE, with typical inflammatory lesions, at a higher frequency than their non-transgenic littermates (Litzenburger et al., 1998) (Table 1); however, the mice did not develop spontaneous EAE, emphasizing the necessity for myelin specific T cell in order to progress the disease. However these last EAE models showed some disadvantages such as the clonal heterogeneity of the T cell populations and the generation after immunization of several T helper cell lineages in vivo, without the possibility to delineate a specific T cell subset involved.

More recently, Jäger et al. (2009) developed a model that allowed the generation of different T helper subsets to induce EAE. In this model, 2D2 T cells were stimulated in vitro, before their transfer, in the absence of antigen-presenting cells (APCs). Specifically, once isolated, CD4\(^+\) T cells were stimulated in vitro using antibodies against CD3 and CD28, cultured with various combinations of cytokines and blocking antibodies to generate Th1, Th2, Th17 and Th9 subsets that were subsequently transferred to naïve host animals. These last experiments further allowed to delineate the central role of Th1/Th17 subsets in the pathogenesis of disease. Recent evidence has indicated the non-obese diabetic (NOD) strain mice, which spontaneously develop diabetes, are also susceptible to EAE upon active immunization with MOG35–55. More specifically, these animals display a RR disease course that is followed by a chronic non-remitting stage (Encinas et al., 1999), much more similar to the disease course observed in MS. Moreover, Anderson and colleagues created a CD4\(^+\) TCR transgenic model for MOG35–55-driven EAE on the NOD background (1C6), which displayed both CD4\(^+\) and CD8\(^+\) MOG35–55-reactive T cells. 1C6 CD8\(^+\) T cells alone can induce optic neuritis and mild EAE with delayed onset; however, 1C6 CD4\(^+\) T cells alone were able to induce severe EAE and predominate in lesions when both cell types are present, thus supporting the central role of CD4\(^+\) T cells in the pathogenesis of disease (Anderson et al., 2012).

3.4. Immune system and pathogenesis of EAE

Substantial evidence from MS subjects indicates that CD8\(^+\) T cells play a key role in the pathogenesis of the disease (Friese and Fugger, 2009; Goverman, 2009; Mars et al., 2011). CD8\(^+\) T cells have been found more representative than CD4\(^+\) T cells in acute and chronic CNS lesions of MS patients (Woodroffe et al., 1986; Hauser et al., 1986; Monteiro et al., 1995; Jacobsen et al., 2002; Junker et al., 2007). Importantly, immunotherapies specifically targeting CD4\(^+\) T cells failed to show significant clinical benefit in MS course, whereas therapies that affect all leukocytes can improve disease progression (Coles et al., 2006). This latter observation led to the development of animal models of MS, by using MOG-immunized mice, to study the role of CD8\(^+\) T cells in the pathogenesis of disease. Specifically, Ford and Evavold (2005) identified MOG37–40, as a minimal peptide, able to induce specific CD8\(^+\) T cell responses in B6 mice.

MOG-immunized mice on the C57BL/6J background also contributed for the identification of CD4\(^+\) T cells that is nowadays...
considered as a major effector cell in EAE, providing an explanation for the strong correlation of MS susceptibility to particular MHC class II alleles. IFN-γ-expressing Th1 cells were initially considered to be the effector CD4+ T cell subset that induced EAE (Sospedra and Martin, 2005). Indeed, adoptive transfer of Th1 clones in mice deficient in T-bet (a transcription factor required for Th1 cell differentiation) is resistant to EAE induction (Baron et al., 1993; Segal and Shevach, 1996; Bettelli et al., 2004). More recently, the finding that interleukin 23 (IL-23) was required for EAE development (Becher et al., 2002) led to the identification of the IL-23-dependent Th17 subset. It is now well established the role of both IFN-γ-producing and IL-17-producing T cells in the pathogenesis of MS and EAE; indeed, both cells have been identified in the CNS and CSF of MS subjects (Traugott and Lebon, 1988; Link et al., 1992; Kebir et al., 2007; Lock et al., 2002; Abromson-Leeman et al., 2009; Peters et al., 2011). Recent studies have identified different types of inflammatory infiltrates in CNS. Th1 cells have been shown to correlate with a predominantly monocytic CNS infiltrate, while Th17 cells were associated with a higher proportion of neutrophils in the CNS infiltrate (Kroenke et al., 2008). Additionally, the clinical symptoms of Th1- and Th17-mediated EAE were found to be different: Th1 cells induced classic EAE, whereas Th17 cells induced an EAE with a more severe clinical phenotype (Cua et al., 2003; Langrish et al., 2005; Jäger et al., 2009) often characterized by atypical manifestations (Stromnes et al., 2008; Domingues et al., 2010). There is also some recent evidence showing that Th1 cells can co-express IL-17 (Kischkel et al., 2010) and IL-17+ IFN-γ+ T cells have been identified in MS brains (Kebir et al., 2009). To understand the role of these cytokines, animal models, that are genetically deficient in IFN-γ or IL-17, have been developed and their susceptibility to EAE has been characterized (Kebir et al., 2009). By contrast, in MS subjects it has been shown that the IFN-γ supplementation exacerbated disease manifestations, thus suggesting that IFN-γ has more disease-enhancing than disease-suppressing activity (Panitch et al., 1987). Regarding studies on Th17 cells, IL-17A- or IL-17 Receptor A-deficient mouse models showed a reduced incidence, severity and a delayed onset of EAE (Hofstetter et al., 2005; Komiyama et al., 2006; Hu et al., 2010). In addition, clinical trials in which RR–MS subjects were treated with an IL-17 neutralized monoclonal antibody, reported a reduction of lesion activity and a trend towards reduced relapse rates (Elain et al., 2014), supporting the central role of Th17 cells and IL-17 cytokine in the pathogenesis of MS.

The discovery of CD4+CD25+ T cells (Tregs), which express the master gene Foxp3 (forkhead box P3), as key players in the control of immune tolerance, allowed to establish an impaired number and functions of these cells in autoimmune disorders such as MS (Kleineuwiedfeld and Hafler, 2014). The majority of these studies was conducted in EAE mice where the adoptive transfer of this T cell subset reduced disease severity (Kohm et al., 2002) and, on the contrary, the administration of anti-CD25 antibody reduced Treg-mediated protection (Reddy et al., 2004; Zhang et al., 2004). Furthermore, the use of the Foxp3-GFP reporter mice facilitated detailed studies of Treg activity. Use of these mice showed that the population of Treg cells in the CNS is initially small but rapidly expands during EAE, and the majority of Tregs in the CNS of EAE mice were found to be antigen specific. Additional support for this approach came from studies that demonstrated impaired function of Tregs in patients with MS. Compared to healthy controls, Tregs isolated from peripheral blood and CSF of MS subjects have significantly reduced suppressive function (Frisullo et al., 2009; Vignetti et al., 2004; Haas et al., 2005). Tregs from MS subjects also exhibited a greater tendency for IFN-γ expression compared to healthy controls (Dominguez-Villar et al., 2011). Recently, CD25, CD127, and CD58, all of which contribute to Treg function, have been identified as risk alleles for susceptibility to MS, further suggesting an intrinsic Treg defect (Baranzini, 2009; Zenewicz et al., 2010; Broux et al., 2010; De Jager et al., 2009). Treating MS patients with IFN-γ appears to restore suppressive function of Tregs (de Andrés et al., 2007; Korporal et al., 2008). Thus, the discovery that enhanced Tregs activity can ameliorate EAE, as well as studies of Tregs activity using reporter mice, have provided insight into current therapies and led to new therapeutic strategies for targeting pathways that enhance Tregs function. However, a note of caution has also emerged from studies using EAE models. Tregs isolated from the CNS during the peak of disease were able to suppress most peripheral effector T cells but failed to inhibit myelin-specific effector T cells isolated from the CNS. This observation suggests that effector T cells in the inflamed CNS may be resistant to suppression by Tregs (Korn et al., 2007).

Over the last few years, a series of molecules known to play a function in metabolism has also been shown to play an important role in the regulation of the immune response. In this context, the adipocyte-derived hormone leptin has been shown to regulate the immune response in normal as well as in pathological conditions. Several studies in EAE mice were conducted to study the role of leptin in MS. It has been shown that leptin-deficient (ob/ob) mice were resistant to a series of experimentally induced autoimmune disorders, including EAE. Normal wild-type mice show increased secretion of leptin in serum upon EAE induction, and brain inflammatory infiltrates stain positive for leptin (Sanna et al., 2003). The same authors also showed an inverse relationship between leptin secretion and the frequency of Treg cells in patients with MS (Matarese et al., 2005) and leptin neutralization with leptin antagonists improves the EAE course by profoundly altering intracellular signaling of myelin-reactive T cells and increasing the number of Treg cells (De Rosa et al., 2006). These data suggest that leptin can be considered as a link among immune tolerance, metabolic state, and autoimmunity and that strategies aimed at interfering with the leptin axis could represent innovative, therapeutic tools for autoimmune disorders.

Recent observations revealed an increased intrathecal produc-

of immunoglobulins (lg) in the CSF of most patients with MS (Owens et al., 2001) thus suggesting a B cell involvement in MS and EAE pathogenesis. Both B cell deficient (μMT−/−) mice and anti-CD20-mediated depletion have been used to investigate the role of B cells in EAE. B10.PL μMT−/− and wild-type mice exhibit similar susceptibility to MBP-peptide induced EAE (Wolf et al., 1996); however, EAE was induced by immunization with recombinant human MOC protein only in wild-type and not in μMT−/− C57BL/6 mice (Oliver et al., 2003; Lyons et al., 1999), thus suggesting a key role displayed by antibodies during immunization with human MOC protein to generate CNS-inflammation. Similar results were obtained in mice expressing a transgenic TCR specific for MOC which developed a very low incidence of spontaneous EAE (Bettelli et al., 2003). In a model of spontaneous RR-EAE in SJL/J mice, expressing a transgenic MOC-specific TCR, B cell depletion suppressed EAE in these mice, providing support for the pathogenic role of B cells. The efficacy of Rituximab, an anti-CD20 antibody, in reducing inflammatory lesions and clinical relapses in patients with RR–MS provides another support for a pathogenic role of B cells in MS (Hauser et al., 2008).

3.5. Limits of EAE

EAE model significantly contributed to our knowledge of autoimmunity and neuroinflammation, changing the course of MS understanding and thus allowing the development of novel therapeutic approaches for this disease. Nonetheless, there are
also several limitations to the use of this animal model because of the differences in the pathogenesis of EAE compared to that of MS. More specifically:

1. EAE model provides very few information about MS progression.
2. The use of C57BL/6 mice does not allow the study of relapses rate.
3. Remyelination is difficult to be studied in EAE. Lesions occur stochastically with regard to timing and localization. Furthermore, mechanistic insights of myelin damage in EAE tissues have not yet been developed.
4. Studies aiming at evaluating the potential benefits of novel therapeutic treatments with neuronal growth and survival factors have been partially successful, as most of the effects were off-target, making any results difficult to interpret (Oliver et al., 2003).
5. EAE is mainly a disease affecting the spinal cord white matter, whereas MS is mainly a brain disease with prominent demyelination of the cerebrospinal cortex. Unfortunately, only very few studies analyzed the involvement of the cortex in EAE.
6. Most forms of EAE are generated by immunization with self-peptide that determines CD4+ T cell activation. Few studies have addressed the role of CD8+ T cells, which are, on the contrary, mainly active in MS lesions and show clonal expansion and activation (Lyons et al., 1999).
7. EAE studies did not extensively analyze the role of B cells in the pathogenesis of the disease (Bettelli et al., 2003), despite recent clinical-trial studies have clearly shown their importance (Hauser et al., 2008).

4. Theiler's murine encephalomyelitis virus (TMEV)

Epidemiological studies have suggested that a viral infection early in life, in the presence of a specific genetic background, may induce an immune-mediated attack against CNS (Poser, 1986; Dal Canto and Lipton, 1977; McFarlin and McFarland, 1982; Kurtzke, 1980), however, there is no specific virus that has been identified as a potential cause or contributor to MS, to date. More recently, Epstein–Barr virus (EBV) infection has been linked to MS as a critical environmental susceptibility factor (De Jager et al., 2008; Ascherio and Munger, 2007; Ascherio et al., 2001). Viral infections of the CNS can induce demyelination in mice and the best studied are the picornavirus, such as Theiler’s murine encephalomyelitis virus (TMEV) and certain strains of the coronavirus, such mouse hepatitis virus (MHV). TMEV is a non-enveloped, positive sense virus that has been identified as a potential cause or contributor to MS, to date. More recently, Epstein–Barr virus (EBV) infection has been linked to MS as a critical environmental susceptibility factor (De Jager et al., 2008; Ascherio and Munger, 2007; Ascherio et al., 2001). Viral infections of the CNS can induce demyelination in mice and the best studied are the picornavirus, such as Theiler’s murine encephalomyelitis virus (TMEV) and certain strains of the coronavirus, such mouse hepatitis virus (MHV). TMEV is a non-enveloped, positive sense, single stranded RNA virus (Tsunoda and Fujinami, 2010) (Table 1) and represents one of the neurotropic viral infection models for MS (Libbey and Fujinami, 2003). TMEV is divided into two subgroups, GDVII and TO, based on the ability to cause disease in the CNS. The GDVII subgroup (strains GDVII and FA) is highly neurovirulent for mice, as it induces death within 1 to 2 weeks. The DA and BeAn8386 (BeAn) strains of the TO subgroup induce acute polioencephalomyelitis. Unlike EAE, the disease is always chronic-progressive in susceptible mice and TMEV can induce inflammatory demyelinating disease only in mice (Owens, 2006) and not in other different species, such as rodents and primates. GDVII virus predominantly infects neurons (Tsunoda et al., 1996) and dying neurons display chromat in condensation and apoptotic (fragmented) nuclei (karyorrhexis) in the absence of inflammatory mononuclear cell (MNC) recruitment. In contrast to GDVII infection, parenchymal as well as perivascular and subarachnoid MNC infiltrates, including CD3+ T cells, are present in the gray matter of the brain (Tsunoda et al., 2007a), during the acute phase of DA infection, while during the chronic phase of DA infection (a month or more after infection), the inflammation in the gray matter of the CNS subsides (Ure and Rodriguez, 2005).

Although axonal damage is observed in MS and its animal model (EAE), it is believed that axonal damage occurs secondarily to severe inflammatory demyelination, where lesions develop from the outside (myelin) to the inside (axon; outside-in model; Tsunoda et al., 2007b). On the contrary, in TMEV infection, axonal damage precedes demyelination (Tsunoda et al., 2003) (inside-out model) and the distribution of damaged axons observed during the early phase corresponds to regions, where subsequent inflammatory demyelination occurs during the chronic phase (Table 1). This evidence suggests that axonal degeneration triggers recruitment of T cells and macrophages into the CNS, leading to subsequent loss of myelin.

4.1. Immune system activation

TMEV persistently infects macrophage/microglia lineage cells, oligodendrocytes and astrocytes during the chronic phase (Lipton et al., 1995). Macrophages have been suggested to play an effector role in demyelination, since their depletion ameliorates TMEV-induced demyelination and intracerebral inoculation with a TMEV-infected macrophage cell line induces acute focal demyelination (Rossi et al., 1997; Rodriguez and Quddus, 1986). Confirming the role of humoral immunity in the pathogenesis of TMEV-induced neurodegeneration, serum anti-TMEV neutralizing antibody responses have been detected within 1 week after infection and high neutralizing antibody titers are seen in mice with persistent TMEV infection (Tsunoda et al., 1996). Moreover, adoptive transfer of neutralizing antibody into TMEV-infected nude mice resulted in viral clearance (Fujinami et al., 1989), suggesting that virus-specific antibody can play a role in viral protection and clearance in vivo.

In this context also TMEV-specific CD4+ T cells play an important role in demyelination, as testified by their infiltration into demyelinating lesions and by the evidence that in vivo depletion of these cells diminished the severity of demyelination. However, Gerety et al. (1994) have shown that TMEV specific CD4+ Th1 cells alone cannot induce demyelination, but that the homing of virus specific T cells into the CNS requires previous virus infection in the CNS. Moreover, it has been recently shown that treatment of TMEV infected mice with ex vivo generated induced Tregs (iTregs) worsened clinical signs of MS when the treatment was performed in the early phase of the disease, but was protective when the treatment was performed in the chronic phase, as it increased IL-10 production from B cells, CD4+ T cells and dendritic cells, which may contribute to the decreased CNS inflammation (Martinez et al., 2014).

With regard to CD8+ T cells, it has been shown that these cells infiltrate the demyelinating lesions, that in vivo administration of CD8 antibody diminishes demyelination, that CD8-deficient SJL mice showed minimal deficits with no effect on the extent of demyelination (Murray et al., 1998) and that MHC class I molecules are up-regulated in the CNS of TMEV-infected mice, thus suggesting that CD8+ T cells play an effector role in TMEV-induced demyelination. However, recent reports have also demonstrated that TMEV infection can result in induction of autoreactive CTLs that recognize both virus and host antigens, potentially leading to CNS pathology (Tsunoda et al., 2002). In TMEV infection, intercellular adhesion molecule (ICAM)-1, leukocyte function-associated antigen (LFA)-1 and vascular cell adhesion molecule (VCAM)-1 are up-regulated in the CNS (Olson et al., 2001); their inhibition resulted in the suppression of demyelinating disease in SJL mice (Mestre et al., 2009). In addition, a decreased number of CD4+ and CD8+ T cells in the brains of the adhesion-molecule deleted mice as compared to control mice has been detected (Njenga et al., 2004).
4.2. Limits and positive aspects of TMEV models

The TMEV model and EAE display several important differences, such as a requirement for viral persistence, immune system activation, neuropathogenetic mechanism, and clinical courses.

The main positive aspect of TMEV model are as follows:

1) Its virus-induced pathology has clear similarities to MS, as the clinical manifestation is very similar to those observed in human chronic progressive MS.
2) Pathological features of virus-induced demyelinating disease are in general mediated by the activation of immune system and not by a direct toxic effect mediated by the virus on the target cells.
3) The TMEV model may be useful for the testing of new therapeutic approaches, particularly for therapies targeting adhesion molecules, axonal degeneration, and immunosuppression.

The main negative aspects (which limit its use) are as follows:

1) Unlike EAE, which is inducible in several different species, such as rodents and primates, TMEV can induce inflammatory demyelinating disease only in mice. Specifically it does not cause pathology in humans. This aspect raised the question whether the virus is rational or not to use a non-human pathogen to characterize a human disease, such as MS.
2) The pathogenesis of TMEV-induced demyelination in part differs from that in human MS, where persistent viral infection of the CNS has not been demonstrated.

5. Toxic models of MS

In addition to the well-characterized experimental approach to induce demyelination in mice, such as autoimmune inflammatory-induced demyelination in EAE, also viral-induced demyelination and toxic demyelination can be performed (Pachner, 2011) (Table 1). While EAE is the most commonly used model to reflect the autoimmune origin of MS, toxic demyelination is more suitable to study the de- and re-myelination processes (Blakemore and Franklin, 2008). Two are the most common agents utilized to induce demyelination: cuprizone and lyssolecithin. Cuprizone (bis-cyclohexanone-oxalidihydrazone) is a copper chelating reagent which, supplemented to normal rodent chow, causes oligodendrogial cell death with subsequent demyelination, together with a damage to adjacent cells and axons; it is not immune-mediated since it occurs even in immune-deficient mice. However, chronic inflammation in lesions is minimal if young animals are used, and complete remyelination occurs in 5–6 weeks; on the contrary, repair in older animals is much slower (Shields et al., 1999). In the acute phase immediately following the lyssolecithin injection, lesion sites are infiltrated with T cells, B cells, macrophages and neutrophils which seem to be involved in CNS repair (Bieber et al., 2003). Infiltration and activation of macrophages and microglia begin within hours after injection and last many days. The role that these cell types play in establishing an environment in which remyelination can occur is not completely known. It is well accepted that the T-cell response promotes the expression of different neurotrophins by macrophages and astrocytes, that sustain neuronal protection and survival. During the remyelination process, several growth factors are produced and T cells might play a similar role in supporting oligodendrocyte remyelination, both directly and indirectly, by stimulating the activity of CNS glia. Moreover, depletion of macrophages impairs per se oligodendrocyte remyelination, thus suggesting a key role for this population in the myelin repair process. Taken together all this evidence suggests that toxin-induced demyelination models, compared to EAE and virus induced demyelinating syndrome, do not reflect MS disease, but are mainly established systems to study the process of de- and remyelination (Blakemore and Franklin, 2008).

6. Development, success and failure of novel therapies for MS tested in animal models

EAE models have historically been used pre-clinically to assess and define the utility of novel MS therapies. The spectrum of agents showing promising results in EAE is extensive and ranges from natural compounds to modern genetic manipulation of the immune system with cytokines and antigen. The most important examples in this context are represented by glatiramer acetate, mitoxantrone and Natalizumab (Kieseier and Hartung, 2003; Steinman and Zamvil, 2006). The glatiramer acetate preparation is a random polymer consisting of repeated sequences of four amino acids, which has been shown to suppress EAE progression, probably through the stimulation of Th2-mediated anti-MBP immune response (Aharoni
et al., 1997, 2008), or by inducing killing of antigen-presenting cells (APCs) and generation of Treg cells (Racke et al., 2010). Mitoxantrone has first been proven to be a powerful immunosuppressive drug in EAE (Ridge et al., 1985), and it is now a second-line component of MS therapy (Hartung et al., 2002). Cytotoxic effects on lymphocytes and induction of apoptosis of APC have been proposed as the major mechanism of action of this drug (Neuhaus et al., 2005; Vollmer et al., 2010). Also Natalizumab, which is a monoclonal antibody (mAb) that inhibits the transmigration of immune cells into the inflamed parenchyma of lymphatic organs and the CNS, has been shown to be effective in preventing EAE (Rice et al., 2005; Yednock et al., 1992). It was of the first mAb approved for therapeutic trials in MS (Polman et al., 2006) and indeed now it represents a second-line drug for MS therapeutic approach.

A recent criticism of EAE has been raised by the fact that several therapeutic approaches that showed promising results in this mouse model, have been shown to be either inefficient or in some cases harmful in human MS (Steinman and Zamvil, 2006). For example, the blockade of three different cytokines, whose activity has been reported to be important in inflammation in EAE, such as TNF-α, BAFF, and IL-23, was found either to worsen MS (Meinl et al., 2011) or to have no effect in humans (Longbrake and Racke, 2009). The same holds true for the neuroprotective polyethylene hormone ciliary neurotrophic factor (CNTF), which elicits an acute-phase response in rat liver (Dittrich et al., 1994), or for the anti-adhesion molecule mAb anti-CD54 (Morrissey et al., 1996), and the phosphodiesterase-4 inhibitor rolipram, which despite its effective role in suppressing EAE, failed to suppress inflammatory activity in a pilot trial in patients with relapsing–remitting MS (Bielekova et al., 2009).

Moreover, in clinical studies aimed at inducing oral tolerance or antigen-specific tolerance to a potential encephalitogenic autoantigen such as MBP, either worsening of disease or no change in the clinical course (Bielekova et al., 2000; Kappos et al., 2000) have been reported. Likewise, there was no beneficial effect of anti-CD4 antibody therapy on the progression of MS, despite the profound decrease of CD4+ T cells in peripheral blood (van Oosten et al., 1997; Lindsey et al., 1994). The reasons for the discrepant results obtained in the animal and human systems could be due to their different genetic natures, different pathogenic mechanisms or kinetic (temporal differences of immune reactivity and response to therapy). Additionally, in MS the blood–brain barrier (BBB) may be insufficiently disrupted as compared to EAE thereby preventing therapeutic molecules to reach their target within the CNS. For all these reasons, EAE has been considered for all these reasons, EAE has been considered a par excellence for shedding light on specific mechanistic questions. Nonetheless, a great number of animal models, developed for MS, have garnered consistent criticism, often resulting in disappointing failures. It is important to remember that there is no a single animal model that can reflect the entire spectrum of heterogeneity of MS and this research field lacks a focused disease model for progressive MS. To approach the complexity of MS, current progress in humanizing the entire immune system in rodents will surely provide substantial advantages for exploring novel immune-modulatory approaches in more appropriate models. In conclusion, despite the clearly existing limitations, basic science on MS will continue to rely on these models for new drug development and for a better comprehension of the different pathogenic mechanisms of MS.

Acknowledgments

G.M. is supported by grants from the European Union IDEAS Programme European Research Council Starting Grant “menTORingTregs” no. 310496, the Fondazione Italiana Sclerosi Multipla (FISM) no. 2012/R/11 and the CNR-Medicina Personalizzata. V.D. R. is also supported by the Ministero della Salute Grant no. GR-2010-2315414 and the Fondo per gli Investimenti della Ricerca di Base (FIRB) Grant no. RBFR12UB_004. The authors wish to thank Maria Rosaria Montagna for technical support, and all members of the Laboratory of Immunology at IEO-CNR for assistance and support. This work is dedicated to the memory of E. Papa and S. Zappacosta.

References

Abroms-bonee-Leenan, S., Bronson, R.T., Dorf, M.E., 2009. Encephalitogenic T cells that stably express both T-bet and ROR-gamma t consistently produce IFN-gamma but have a spectrum of IL-17 profiles. J. Neuroimmunol. 215, 10–24.
Adlard, K., Tsiaknaris, L., Beam, A., Beho Jr., B.F., Vandenbark, A.A., Offner, H., 1999. Immunoregulation of encephalitogenic MBP-NAc1–11–reactive T cells by CD4+ TCR-specific T cells involves IL-4, IL-10 and IFN-gamma. Autoimmunity 31, 237–248.
Aharoni, R., Herschkovitz, A.,Elam, I., Blumberg-Hazan, M., Sela, M., Brü ck, W., Arnon, R., 2008. Denervation arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 105, 11352–11357.
Aharoni, R., Teitelbaum, D., Sela, M., Arnon, R., 1997. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 94, 10821–10826.
Anderson, A.C., Chandwaskar, R., Lee, D.H., Sullivan, J.M., Solomon, A., Rodriguez-Manzanet, R., Greve, B., Soler, R.A., Kuchroo, V.K., 2012. A transgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ T cells. J. Immunol. 188, 2084–2092.
Ascherio, A., Mungl, K.L., 2007. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61, 288–299.
Ascherio, A., Mungl, K.L., Lennette, E.T., Spiegelman, D., Hernan, M.A., Olek, M.J., Hankinson, S.E., Hunter, D.J., 2001. Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. J. Am. Med. Assoc. 286, 3083–3088.
Baranzini, S.E., 2009. The genetics of autoimmune diseases: a networked perspective. Curr. Opin. Immunol. 21, 596–605.
Baron, J.L., Madra, J.A., Ruddle, N.H., Hashim, G., Janeway Jr., C.A., 1993. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177, 57–68.
Batoulis, H., Recks, M.S., Adelstein, R.S., Guertzen, S., 2011. Experimental autoimmune encephalomyelitis e achievements and prospective advances. Acta Pathol. Microbiol. Immunol. Scand. 119, 819e30.
Becher, B., Durrell, B.G., Noelle, R.J., 2002. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Investig. 110, 493–497.
Benardais, K., Kotis, A., Sinkjuc, J., Koutoudaki, P.N., Gud, V., Singh, V., Vulinovici, F., Skripuletz, T., Stangel, M., 2013. Cuprizone (Bis(Cyclohexylidenehydrazide)) is selectively toxic for mature oligodendrocytes. Neurorot. Res. 24, 244–250.
Berard, J.L., Wolak, K., Fournier, S., David, S., 2010. Characterization of relaxing remitting and chronic forms of experimental autoimmune encephalomyelitis in C57Bl/6 mice. Glia 58, 434645.
Bettelli, E., Pagany, M., Weiner, H.L., Uinnington, C., Solbel, R.A., Kuchroo, V.K., 2003. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 197, 1073–1081.
Bettelli, E., Sullivan, B., Szabo, S.J., Solbel, R.A., Glimcher, L.H., Kuchroo, V.K., 2004. Loss of T-bet, but not STAT-1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 200, 79–87.
Bieber, A.J., Kerrr, S., Rodriguez, M., 2003. Efficient central nervous system remyelination requires T cells. Ann. Neurol. 53, 680–684.
Bielekova, B., Goodwin, B., Richert, N., Cortese, L., Kondo, T., Afsar, G., Gran, R., Eaton, J., Antel, J., Frank, J.A., McFarland, H.F., Martin, R., 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6, 1167–1175.
Bielekova, B., Richert, N., Howard, T., Packer, A.N., Blevins, G., Olayon, J., McFarland, H.F., Struzebecher, C.S., Martin, R., 2009. Treatment with the phosphodiesterase type 4 inhibitor rolipram fails to inhibit blood–brain barrier disruption in multiple sclerosis. Mol. Scler. 15, 1206–1214.
Blakemore, W.F., Franklin, R.J., 2008. Remyelination in experimental models of toxin-induced demyelination. Curr. Top. Microbiol. Immunol. 318, 193–212.
Brouwers, J., Eijlings, N., Venken, K., Rummens, J.L., Henssen, K., Van Wijmorsch, R., Stinus, P., 2010. Halotropy 4 of the multiple sclerosis-associated interleukin-7 receptor alpha gene influences the frequency of recent thymic emigrants. Genes Immun. 11, 326–333.
Shields, S.A., Gilson, J.M., Blakemore, W.F., Franklin, R.J., 1999. Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotxin-induced CNS demyelination. Glia 28, 77–83.

Sospedra, M., Martin, R., 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683–747.

Siram, S., Steiner, I., 2005. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Annu. Neurol. 58, 939–945.

Steinman, L., Zamvil, S.S., 2006. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Annu. Neurol. 60, 12–21.

Stromnes, I.M., Cerretti, L.M., Liggitt, D., Harris, R.A., Goverman, J.M., 2008. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 14, 337–342.

Tsunoda, I., Fujinami, R.S., 2010. Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis. J. Neuroimmunol. 3, 355–369.

Tsunoda, I., Iwasaki, Y., Terunuma, H., Sako, K., Ohara, Y., 1996. A comparative study of acute and chronic diseases induced by two subgroups of Theiler's murine encephalomyelitis virus. Acta Neuropathol. 101, 595–602.

Tsunoda, I., Kvam, L-Q., Fujinami, R.S., 2002. Induction of autoreactive CD4+ cytotoxic T cells during Theiler's murine encephalomyelitis virus infection: implications for autoimmunity. J. Virol. 76, 12834–12844.

Tsunoda, I., Kvam, L-Q., Libbey, J.E., Fujinami, R.S., 2003. Axonal injury heralds virus-induced demyelination. Am. J. Pathol. 162, 1239–1269.

Tsunoda, I., Libbey, J.E., Fujinami, R.S., 2007a. TGF-β1 suppresses T cell infiltration and VP2 puff B mutation enhances apoptosis in acute polioencephalitis induced by Theiler's virus. J. Neuroimmunol. 190, 80–89.

Tsunoda, I., Tanaka, T., Sajioh, Y., Fujinami, R.S., 2007b. Targeting inflammatory demyelinating lesions to sites of Wallerian degeneration. Am. J. Pathol. 171, 1563–1575.

Tuohy, V.K., Lu, Z., Sobel, R.A., Laursen, R.A., Lees, M.E., 1989. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142, 1523e7.

Ure, D.R., Rodriguez, M., 2005. Histopathology in the Theiler's virus model of demyelination. In: Lavi, E., Constantinescu, C.S. (Eds.), Experimental Models of Multiple Sclerosis. Springer, New York, pp. 579–591.

van Oosten, B.W., Lai, M., Hodgkinson, S., Barkhof, F., Miller, D.H., Moseley, I.F., Thompson, A.J., Rudge, P., McDougall, A., McLeod, J.C., Ad lr, H.J., Polman, C.H., 1997. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cMT412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49, 351–357.

Viglietta, V., Baeche-Allan, C., Weiner, H.L., Hafler, D.A., 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patientswhos thrive multiple sclerosis. J. Exp. Med. 199, 971–979.

Vollmer, T., Stewart, T., Baxter, N., 2010. Mitoxantrone and cytotoxic drugs mechanisms of action. Neurology 74 (Suppl. 1), S41–S46.

Wensky, A.K., Furtado, G.C., Marcondes, M.G., Chen, S., Manfa, D., Lira, S.A., Zagzag, D., Lafaille, J.J., 2005. IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis. J. Immunol. 174, 1416–1423.

Whitham, R.H., Bourdette, D.N., Hashim, G.A., Herndon, R.M., Ilg, R.C., Vandenberg, A.A., Offner, H., 1991. Lymphocytes from SJL mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 146, 101–107.

Wolf, S.D., Dittel, B.N., Hardardottir, F., Janeway Jr., C.A., 1996. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184, 2271–2278.

Woodroofe, M.N., Bellamy, A.S., Feldmann, M., Davison, A.N., Cuzner, M.L., 1986. Immunocytotoxicchemical characterisation of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth. J. Neurol. Sci. 74, 125–152.

Yednock, T.A., Cannon, C., Fritz, L.C., Sanchez-Madrid, F., Steinman, L., Karin, N., 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356, 63–66.

Zamvil, S., Nelson, P., Trotter, J., Mitchell, D., Knobler, R., Fritz, R., Steinman, L., 1985. CD4+ T-cell clonesspecific for myelin basic protein induce chronic relapsing paralyis and demyelination. Nature 317, 355–358.

Zenewicz, L.A., Abraham, C., Flavell, R.A., Cho, J.H., 2008. Unraveling the genetics of autoimmune encephalomyelitis. Cell 140, 791–797.

Zhang, X., Koldzic, D.N., Izikson, L., Reddy, J., Nazareno, R.F., Sakaguchi, S., Kuchroo, V.K., Weiner, H.L., 2004. Flt-1 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int. Immunol. 16, 249–256.